Nuvalent NUVL
NUVL
$123.96 +0.00 (+0.00%)
At close: Jul 21, 2026 · 4:00 PM EDT

Nuvalent (NUVL) Accumulated Expenses (2020 - 2026)

Nuvalent's (NUVL) quarterly Accumulated Expenses came in at $8.2 million in Q1 2026, down 83.19% YoY from $48.9 million in Q1 2025, and down 86.54% on a QoQ basis from $61.0 million in Q4 2025.

Analysis

Nuvalent (NUVL) Accumulated Expenses (2020 - 2026) Analysis & Trends

Nuvalent (NUVL) has 7 years of Accumulated Expenses data on file, last reported at $8.2 million in Q1 2026.

  • Quarterly Accumulated Expenses fell 83.19% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 83.19% YoY) and the FY2025 annual result came in at $61.0 million, up 483.74% from the prior year.
  • Accumulated Expenses eased to $8.2 million in Q1 2026, from $61.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $61.8 million in Q2 2025 to a low of $3.9 million in Q1 2022.
  • A 5-year average of $21.7 million and a median of $12.3 million in 2022 frame the typical range for Accumulated Expenses.
  • Annual changes were most pronounced in 2025 — Accumulated Expenses jumped 483.74% — and 2026, when it tumbled 83.19%.
  • Tracing NUVL's Accumulated Expenses over 5 years: stood at $12.3 million in 2022, then slumped by 40.37% to $7.3 million in 2023, then surged by 42.67% to $10.5 million in 2024, then jumped by 483.74% to $61.0 million in 2025, then plunged by 86.54% to $8.2 million in 2026.
  • The last three Accumulated Expenses figures came in at $8.2 million (Q1 2026), $61.0 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Nuvalent 9.75 Bn 9.75 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 58.92 Mn
Dec 31, 2025 61.01 Mn
Sep 30, 2025 67.14 Mn
Jun 30, 2025 61.81 Mn
Mar 31, 2025 48.87 Mn
Dec 31, 2024 48.80 Mn
Sep 30, 2024 35.20 Mn
Jun 30, 2024 30.79 Mn
Mar 31, 2024 20.03 Mn
Dec 31, 2023 22.55 Mn
Sep 30, 2023 19.32 Mn
Jun 30, 2023 12.68 Mn
Mar 31, 2023 10.59 Mn
Dec 31, 2022 12.29 Mn
Sep 30, 2022 8.36 Mn
Jun 30, 2022 6.01 Mn
Mar 31, 2022 3.88 Mn
Dec 31, 2021 5.89 Mn
Sep 30, 2021 4.31 Mn
Jun 30, 2021 2.03 Mn